MorphoSys US Inc.

https://www.morphosys.com

MorphoSys (FSE & NASDAQ: MOR) is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of exceptional, innovative therapies for patients suffering from serious diseases. The focus is on cancer. Based on its leading expertise in antibody, protein and peptide technologies, MorphoSys, together with its partners, has developed and contributed to the development of more than 100 product candidates, of which 29 are currently in clinical development. In 2017, Tremfya(R), marketed by Janssen for the treatment of plaque psoriasis, became the first drug based on MorphoSys's antibody technology to receive regulatory approval. The Company's most advanced proprietary product candidate, MOR208, has been granted U.S. FDA breakthrough therapy designation for the treatment of patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL). Headquartered near Munich, Germany, the MorphoSys group, including the fully owned U.S. subsidiary MorphoSys US Inc., has approximately 320 employees. *

	Start	2018-07-24 established (approx)
	Group	MorphoSys (Group)
	Industry	therapeutic antibody
	Industry 2	Ylanthia® antibody technology
	Person	Trexler, David R. (MorphoSys 201902– President of MorphoSys US Inc before EMD Serono + Eisai Inc + Mylan Bertek)
	Person 2	Herron, Jennifer (ADC Therapeutics 201911–202212 CCO based in US before Immunogen + MorphoSys LEFT 12/22)

	Region	Boston, MA
	Country	United States (USA)
	Street	470 Atlantic Avenue
	City	Boston, MA
		Address record changed: 2020-12-02

Basic data	Employees	n. a.

		* Document for »About Section«: MorphoSys AG. (1/31/19). "Press Release: MorphoSys Announces Settlement in Patent Lawsuit with Janssen and Genmab". Planegg.

		Record changed: 2023-07-10